Search results
Added:
9 months ago
Source:
Radcliffe Cardiology
AUTHOR: Jennifer ThomasThe long-standing debate over the benefits of heart rate (HR)-lowering drug treatment, particularly in patients with hypertension, has been addressed in a new large-scale meta-analysis. The findings, published in the European Heart Journal, suggest that the advantages of reducing HR are highly dependent on the patient's underlying clinical condition, with significant…
View more
Added:
4 weeks ago
Source:
Radcliffe CVRM
A spectrum of primary aldosteronism, indicated by a higher aldosterone-renin ratio (ARR), may contribute to an increased risk of atrial fibrillation (AF) and ischaemic stroke in older adults, according to a new cohort study analysis.¹MethodologyThis prospective cohort analysis used data from the Atherosclerosis Risk in Communities (ARIC) study. The investigation included 3,477 community-dwelling…
View more
Added:
8 months ago
Source:
Radcliffe CVRM
A prespecified secondary analysis of the EAST-AFNET 4 trial has found that the benefits of an early rhythm control strategy for patients with recently diagnosed atrial fibrillation (AF) are maintained regardless of whether patients have obesity or diabetes.¹ These findings suggest that clinicians should not withhold this therapeutic approach based on these common metabolic comorbidities.The…
View more
Increased Systolic Blood Pressure Variability Over Time Linked to Higher Risk of CVD, CKD, and Death
Added:
9 months ago
Source:
Radcliffe CVRM
News
Added:
1 month ago
Source:
Radcliffe CVRM
Renin-independent aldosteronism is a common and often underrecognised condition. A new analysis from the Atherosclerosis Risk in Communities (ARIC) study has investigated whether this broader spectrum of aldosteronism is associated with incident cardiovascular disease (CVD) in older, community-dwelling adults.¹MethodologyThis prospective cohort analysis included 3,477 participants from the ARIC…
View more
Added:
2 weeks ago
Source:
Radcliffe CVRM
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have established cardiorenal benefits in type 2 diabetes, long-term data for their use in patients with type 1 diabetes (T1D) have been scarce. A new large-scale study suggests that initiating GLP-1RA therapy is associated with a lower risk of major adverse cardiovascular and kidney outcomes in this population, without compromising safety…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
A new scientific statement from the American Heart Association (AHA) and American College of Cardiology (ACC) outlines the rationale behind the updated 2025 High Blood Pressure Guideline, which recommends a shift in cardiovascular risk assessment. The guideline now endorses the use of the Predicting Risk of Cardiovascular Disease Events (PREVENT) equations to guide the initiation of…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
An artificial intelligence (AI)-augmented clinical programme may significantly improve the detection of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is frequently underdiagnosed, according to the results of a new nonrandomized clinical trial.¹ The study evaluated an AI model, ATTRACTnet, in a real-world setting to identify patients missed by usual care.The ATTRACTnet model was…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
A recent phase 2 trial has indicated that BI 764198, a novel, selective transient receptor potential cation channel, subfamily C, member 6 (TRPC6) inhibitor, significantly reduces proteinuria in patients with focal segmental glomerulosclerosis (FSGS).¹ Overactivity of TRPC6 is believed to contribute to podocyte loss and the progressive decline in kidney function characteristic of FSGS.BI 764198…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
Late-breaking results from the pivotal Phase III FINE-ONE study show that finerenone significantly reduces the urine albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D).² The findings, presented at the American Society of Nephrology’s Kidney Week 2025, mark the first positive Phase III results for a new therapy in this high-risk…
View more